Skip to main content
. 2017 Nov 6;103(1):320–327. doi: 10.1210/jc.2017-01525

Table 1.

Effect of Cosyntropin on Steroid Concentrations and Ratios in the AV and IVC

A. Steroid Concentrations in the AV and IVC
Steroid Precosyntropin Postcosyntropin Fold Change (Post/Pre)
AV (nmol/L) IVC (nmol/L) AV/IVC(P Value) AV (nmol/L) IVC (nmol/L) AV/IVC(P Value) AV (P Value) IVC (P Value)
PregS 100 [54–210] 66 [26–84] 1.9 (0.02) 2996 [2563–4833] 91 [66–161] 32 (<0.0001) 32 (<0.0001) 1.7 (0.006)
17OHPregS 22 [11–41] 6.0 [3.0–16] 3.4 (0.0008) 554 [422–840] 16 [12–20] 35 (<0.0001) 29 (<0.0001) 3.0 (0.002)
DHEAS 2374 [1772–3561] 2187 [1351–3409] 1.2 (0.3) 4730 [2788–6514] 2185 [1271–2882] 2.2 (0.001) 1.8 (0.02) 1.0 (0.8)
AdiolS 330 [170–804] 351 [185–773] 1.0 (0.9) 316 [179–753] 322 [200–723] 1.0 (>0.99) 1.0 (>0.99) 1.0 (0.9)
Preg 2.8 [1.8–4.0] 1.3 [0.8–2.6] 2.1 (0.003) 1502 [1280–1900] 2.6 [2.1–4.3] 551 (<0.0001) 578 (<0.0001) 2.0 (0.0009)
17OHPreg 10 [6.7–25] 0.9 [0.2–3.2] 32 (<0.0001) 2863 [2280–3542] 7.7 [4.3–13] 370 (<0.0001) 267 (<0.0001) 7.1 (<0.0001)
DHEA 36 [26–75] 11 [3.5–20] 5.0 (<0.0001) 1725 [1304–3198] 15 [5.3–30] 134 (<0.0001) 49 (<0.0001) 1.3 (0.3)
B. Steroid Ratios in the AV and IVC
Steroid Ratios Precosyntropin Postcosyntropin Fold Change (Post/Pre)
AV IVC AV/IVC (P Value) AV IVC AV/IVC (P Value) AV (P Value) IVC (P Value)
PregS/Preg 28 [14–49] 41 [27–54] 0.9 (0.2) 2.2 [1.8–2.6] 37 [27–47] 0.06 (<0.0001) 0.07 (<0.0001) 0.9 (0.6)
17OHPregS/17OHPreg 1.4 [0.8–2.3] 4.9 [2.3–32] 0.3 (0.0002) 0.2 [0.1–0.3] 2.0 [1.4–5.2] 0.08 (<0.0001) 0.2 (<0.0001) 0.4 (0.04)
DHEAS/DHEA 73 [38–92] 223 [140–382] 0.3 (<0.0001) 2.5 [2.0–3.6] 163 [120–263] 0.01 (<0.0001) 0.04 (<0.0001) 0.7 (0.1)
DHEAS/PregS 24 [12–49] 36 [28–62] 0.7 (0.07) 1.3 [0.8–2.7] 22 [14–32] 0.07 (<0.0001) 0.05 (<0.0001) 0.6 (0.003)
DHEA/Preg 13 [9.5–20] 6.9 [4.6–9.1] 1.9 (0.003) 1.2 [0.7–1.9] 4.4 [2.8–8.7] 0.3 (<0.0001) 0.1 (<0.0001) 0.8 (0.1)

LC-MS/MS was used to quantify the unconjugated Δ5 steroids and steroid sulfates in paired AV and the IVC before and after 10 to 30 minutes of cosyntropin administration (injected as a 0.125-mg bolus followed by a 0.125-mg/h continuous infusion). Data are expressed as median [interquartile range]. AV/IVC is expressed as median of individual ratios with [interquartile range]. Statistical significance was determined by paired t test (P < 0.05). To convert nmol/L to ng/dL, multiply by the following correction factors: Preg, 31.65; 17OHPreg, 33.25; DHEA, 28.84; PregS, 39.65; 17OHPregS, 41.25; DHEAS, 36.85; and AdiolS, 37.05.

HHS Vulnerability Disclosure